TRAX

First Tracks Biotherapeutics, Inc.

First Tracks Biotherapeutics, Inc. (TRAX) is rated C (2.3/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Momentum (B+); its weakest is Profitability (D-). The rating has held at C for 7 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.3 / 5.0
C
Value
C+
Factor Score 2.5 / 5.0
Growth
C-
Factor Score 2.0 / 5.0
Profitability
D-
Factor Score 0.8 / 5.0
Momentum
B+
Factor Score 3.7 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -13.4
EV / EBITDA -11.6
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M 8.0%
Price Return 12M 147.9%
Catalyst Signal 0.00
Market Cap $2.0B
TTM Revenue N/A
Price / Sales N/A
ROE N/A

Historical Factor Score Progression

Held C for 7 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-15 C+ (2.5) C- (2.0) D- (0.8) B+ (3.7) C+ (2.6) C (2.3)
2026-11-08 C+ (2.5) C- (2.0) D- (0.8) B (3.4) C+ (2.6) C (2.3)
2026-11-01 C+ (2.5) C- (1.9) D- (0.8) B (3.3) C+ (2.7) C (2.3)
2026-10-25 C+ (2.5) C- (1.9) D- (0.8) B+ (3.5) C+ (2.6) C (2.3)
2026-10-18 C+ (2.5) C- (1.9) D- (0.8) B+ (3.6) C+ (2.6) C (2.3)
Page 1 of 3